Page last updated: 2024-10-24

carmustine and Branch Vein Occlusion

carmustine has been researched along with Branch Vein Occlusion in 1 studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Research Excerpts

ExcerptRelevanceReference
"One patient had a retinal vein thrombosis."2.39Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. ( Baars, JW; de Glas-Vos, CW; Rodenhuis, S; Thomas, BL; van der Lelie, H; van Dijk, MA; van Oers, RH; von dem Borne, AE, 1995)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
van der Lelie, H1
Baars, JW1
Rodenhuis, S1
van Dijk, MA1
de Glas-Vos, CW1
Thomas, BL1
van Oers, RH1
von dem Borne, AE1

Reviews

1 review available for carmustine and Branch Vein Occlusion

ArticleYear
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support.
    Cancer, 1995, Dec-01, Volume: 76, Issue:11

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An

1995